PDF(Pubmed)
Abstract：
Low-grade serous ovarian cancer (LGSOC) is a very rare histological subtype of serous ovarian cancer, representing ~2% of all epithelial ovarian cancer cases. LGSOC has a better prognosis but a lower response rate to chemotherapy in comparison to high-grade serous ovarian carcinoma (HGSOC). The present study is a retrospective review of the medical records of all patients with histologically proven LGSOC diagnosed and treated in a single institute between January 2003 and December 2019. A total of 23 patients diagnosed with LGSOC and treated at King Faisal Specialist Hospital and Research Center (Riyadh, Saudi Arabia) were identified. The median age at diagnosis was 45.5 years (range, 26-66 years) and the median body mass index was 26.1 (range, 18-43). A total of 21 patients (91.3%) had de novo LGSOC, whereas only 2 patients (8.7%) had LGSOC that had transformed from serous borderline ovarian tumors and recurred. A total of 8 patients (34.8%) were diagnosed with International Federation of Gynecology and Obstetrics stage IV, whereas 3 (13.0%), 3 (13.0%) and 9 (39.1%) were diagnosed with stages I, II and III, respectively. In addition, 10 (43.5%), 5 (21.7%), and 3 (13.0%) patients had complete response, stable disease and partial response statuses after first-line therapy, respectively. At a median follow-up time of 34 months [95% confidence interval (CI), 25.32-42.69], the median progression-free survival (PFS) time was 75.2 months (95% CI, 17.35-133.05) and the median overall survival (OS) time was not reached. In conclusion, LGSOC exhibited better PFS and OS times than HGSOC as compared with data from the literature, and there is the option for systemic treatment (chemotherapy or hormonal therapy). Optimal cytoreduction showed numerically higher, but non-significant, PFS and OS times compared with suboptimal debulking; however, the optimal systemic chemotherapy or hormonal treatment remains controversial.
摘要：
低级别浆液性卵巢癌（LGSOC）是浆液性卵巢癌的一种非常罕见的组织学亚型，约占所有上皮性卵巢癌病例的2%。与高级别浆液性卵巢癌（HGSOC）相比，LGSOC具有更好的预后，但对化疗的反应率较低。本研究是对2003年1月至2019年12月在单一机构中诊断和治疗的所有经组织学证实的LGSOC患者的医疗记录的回顾性回顾。共有23例诊断为LGSOC并在费萨尔国王专科医院和研究中心（利雅得，沙特阿拉伯）已确定。诊断时的中位年龄为45.5岁（范围，26-66岁)，中位体重指数为26.1(范围，18-43).共有21例患者(91.3%)有从头LGSOC，而只有2例患者(8.7%)的LGSOC从浆液性交界性卵巢肿瘤转化并复发.共有8例(34.8%)被诊断为国际妇产科联合会IV期,而3（13.0%），3（13.0%）和9（39.1%）被诊断为I期，II和III,分别。此外,10（43.5%），5（21.7%），3例（13.0%）患者完全缓解，一线治疗后疾病稳定和部分反应状态，分别。中位随访时间为34个月[95%置信区间(CI)，25.32-42.69]，中位无进展生存期(PFS)时间为75.2个月(95%CI,17.35~133.05),未达到中位总生存期(OS)时间.总之,与文献数据相比，LGSOC表现出比HGSOC更好的PFS和OS时间，并且有全身治疗（化疗或激素治疗）的选择。最佳的细胞还原显示数值更高，但不重要，PFS和OS时间与次优剔除相比；然而，最佳的全身化疗或激素治疗仍存在争议.
